Chargement en cours...
Disparities in the early adoption of chemo-immunotherapy for diffuse large B-cell lymphoma in the United States
BACKGROUND: Since the 1970s, CHOP chemotherapy has been the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL). In 2002, randomized trials changed this standard by demonstrating that adding rituximab immunotherapy to CHOP improved survival. However, how these results influenc...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4155492/ https://ncbi.nlm.nih.gov/pubmed/22771484 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-12-0466 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|